Credit: Shutterstock photoFor Immediate Release
Chicago, IL - December 16, 2016 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include FedEx (NYSE: FDX - Free Report ), Express Scripts (NASDAQ: ESRX - Free Report ), Mondelez (NASDAQ: MDLZ - Free Report ), Lockheed Martin (NYSE: LMT - Free Report ) and Medtronic (NYSE: MDT - Free Report ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Thursday's Analyst Blog:
Top Research Reports for Thursday
We are featuring fresh research reports on 16 major stocks in today's Research Daily, including reports on FedEx (NYSE: FDX - Free Report ), Express Scripts (NASDAQ: ESRX - Free Report ) and Mondelez (NASDAQ: MDLZ - Free Report ). These reports were hand picked from the roughly 70 research reports issued by our analyst team today. You can see all of today's research reports here >>>>
FedEx shares have handily outperformed the broader market, the Zacks Air Freight industry as well as UPS shares in the year-to-date period (the stock is up +32.9% vs. +21.9% for UPS). The company's status as the package deliverer has made it a proxy for the secular growth in e-commerce. The full extent of FedEx's volume gains this holiday shopping season will not show up in the company's coming quarterly results, which come out on Tuesday next week (the Tuesday report will show results for the fiscal quarter ending on November 30th); we will see that in the following quarterly report. Estimates for the November quarter have modestly gone up lately, with the company expected to earn $2.92 per share in earnings on $14.9 billion in revenues, which represent year-over-year growth rates of +13% and +19.5%, respectively. (You can read the full research report on FedEx here>> )
Express Scripts shares have suffered year to date, losing -19.3%, on persistent macro concerns about drug pricing and other regulatory issues that haven't gone away even after the election. The Zacks analyst points out in the updated research report issued today that the market has likely already priced all these negatives. On the flip side, the analyst points out that Express Scripts stands to benefit from increased generic utilization, shift toward mail orders, strong specialty growth and an aging population. The company is focused on the development of both specialty drugs and generics, which are expected to account for 50% of the total drug spend by 2018. (You can read the full research report on Express Scripts here>> )
Buy-rated Mondelez shares have lagged this year - the stock is down -4.5% vs. +6.2% gain for the Zacks Food Preparation industry in the year-to-date period. The uncertain economic backdrop, particularly in emerging markets (about 80% of Mondolez's sales come from international markets), has been a headwind for the company's volumes and demand. The continued uptrend in the exchange value of the U.S. dollar isn't helping matters either. , losing 4.5%. Mondelez's volumes have been hurt since 2014 by the elasticity impact from higher pricing and category weakness because of soft consumer demand. Moreover, with around 80% of its sales coming from the international markets, currency is a significant top-line headwind. However, estimates for the current year have moved up lately in response to management's concerted efforts to squeeze costs out of the operations and push margins higher. (You can read the full research report on Mondelez here>> )
Other noteworthy reports we are featuring today include Lockheed Martin (NYSE: LMT - Free Report ) and Medtronic (NYSE: MDT - Free Report ).
Free Access: All Zacks Research Reports Starting today, you are invited to download in-depth analysis reports covering more than 1,000 of the most widely followed stocks. Valued at $25 each, they are yours to consult over the next 30 days absolutely free. They feature sensitive Zacks Rank information on each stock that you won't find anywhere else. See the reports free >>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today .
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros .
Get the full Report on FDX - FREE
Get the full Report on ESRX - FREE
Get the full Report on MDLZ - FREE
Get the full Report on LMT - FREE
Get the full Report on MDT - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
FEDEX CORP (FDX): Free Stock Analysis Report
EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report
MONDELEZ INTL (MDLZ): Free Stock Analysis Report
LOCKHEED MARTIN (LMT): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
